Compounding HRT Solutions for Anti-Aging Hormone Therapy

According to NAMS (The Menopause Society) and NIH MedlinePlus, in the context of age-related hormonal decline, decreased libido may present as a sustained reduction in sexual interest, fewer spontaneous thoughts about sex, and diminished desire to initiate intimacy. Associated features may include reduced physical arousal, vaginal dryness, lower genital sensitivity, and diminished or delayed orgasm. According to the Endocrine Society Clinical Practice Guideline, these changes may reflect declining levels of estrogen or testosterone and are distinct from a primary psychiatric disorder. Patients experiencing significant or distressing changes in sexual function should seek evaluation from a qualified clinician; sudden or severe symptoms may indicate an underlying medical condition requiring prompt attention.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, fatigue associated with age-related hormonal changes may present as persistent tiredness that is not fully relieved by rest, reduced motivation, and decreased stamina during daily activities. According to NAMS (The Menopause Society), fatigue in this context may reflect disrupted sleep, vasomotor symptoms, or changes in hormonal milieu including declining estrogen or testosterone levels. Patients experiencing severe, sudden, or worsening fatigue should seek evaluation from a qualified clinician, as fatigue may indicate conditions requiring medical assessment beyond hormonal considerations.

According to the Endocrine Society Clinical Practice Guideline and NIH MedlinePlus, age-related hormonal changes may be associated with progressive reduction in muscle mass and strength — a process sometimes referred to clinically as sarcopenia. This may present as decreased ability to lift objects, slower recovery after exertion, increased effort during routine tasks, and subtle changes in balance or gait. According to the Endocrine Society, these changes may reflect diminished support from anabolic hormones including estrogen, testosterone, or growth hormone. Patients noticing significant or rapid changes in muscle function should seek evaluation from a qualified clinician, as these symptoms may indicate underlying medical conditions requiring comprehensive assessment.

According to NAMS (The Menopause Society) and the Endocrine Society Clinical Practice Guideline, mood disturbances associated with age-related hormonal changes may be characterized by mood variability, increased irritability, periods of anxiety, or low mood. According to NAMS, these symptoms may reflect fluctuating levels of estrogen, progesterone, or testosterone rather than a fixed psychiatric disorder, and may co-occur with changes in concentration, motivation, and sleep quality. Patients experiencing significant mood symptoms should seek evaluation from a qualified clinician; severe or persistent mood changes, particularly those accompanied by thoughts of self-harm, require urgent medical attention.

According to the FDA-approved prescribing information for AndroGel, AndroGel is a topical testosterone gel indicated for testosterone replacement therapy in adult males with primary hypogonadism or hypogonadotropic hypogonadism — conditions of confirmed, clinically significant androgen deficiency. The labeling describes transdermal absorption that may produce steady serum testosterone concentrations. Per the labeling, risks may include virilization in women and children through secondary exposure, changes in lipid profiles, and polycythemia; regular monitoring of testosterone levels and clinical response is described as important. According to the Endocrine Society Clinical Practice Guideline, testosterone therapy in women is not an FDA-labeled indication and, when considered at all, requires specialized clinical judgment and close monitoring. Any compounded preparation involving testosterone is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available AndroGel products are separately regulated, and clinical decisions belong with the prescribing clinician.

According to the FDA-approved prescribing information for Premarin, Premarin is a preparation of conjugated estrogens derived from the urine of pregnant mares, indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, moderate to severe symptoms of vulval and vaginal atrophy, hypoestrogenism due to hypogonadism, castration, or primary ovarian insufficiency, abnormal uterine bleeding, palliation of advanced androgen-dependent carcinoma of the prostate, palliation of metastatic breast cancer, and prevention of postmenopausal osteoporosis. The labeling includes a boxed warning: increased risks of endometrial cancer in patients with a uterus who use unopposed estrogens; estrogens with or without progestins should not be used for prevention of cardiovascular disease or dementia; the Women's Health Initiative reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis. Per the labeling, prescribers should use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Any compounded preparation involving conjugated estrogens is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Premarin products are separately regulated, and clinical decisions belong with the prescribing clinician.